CervoMed (CRVO) Stock: Buy, Sell, or Hold?
CRVO - CervoMed Inc. Common Stock
$2.33
-0.01 (-0.43%)
▼
5d:
+3.56%
30d:
-7.17%
90d:
-12.41%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 06, 2026
14d
Get Alerted When CRVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRVO is currently trading at $2.33, which is considered slightly low relative to its 30-day fair value range of $2.29 to $2.99.
Technical Outlook: Technically, CRVO is in a downtrend. Immediate support is located at $2.13, while resistance sits at $3.33.
Market Sentiment: CRVO scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+541.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRVO is in a downtrend. Immediate support is located at $2.13, while resistance sits at $3.33.
Market Sentiment: CRVO scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+541.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.29 -
$2.99
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 541.0% below Wall St target ($15.00)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.29 -
$2.99
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.13
Resistance Level
$3.34
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.69
Wall Street Target
$15.00
(+541.0%)
Revenue Growth (YoY)
-99.6%
Share & Embed Analysis
Last updated: October 22, 2026 11:28 AM ET
Data refreshes hourly during market hours. Next update: 12:28 PM
Data refreshes hourly during market hours. Next update: 12:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
